The Benchmark Company as co-manager for MTBC’s Upsizing and Pricing of $24.0 Million Public Offering of Preferred Stock
The Benchmark Company’s Senior Equity Analyst, Aydin Huseynov, M.D., CFA. on emergency use of convalescent plasma to treat COVID-19